Loading stock data…
VivoSim Labs (VIVS)
$1.05+0.03 (+2.45%)
Market OpenUpdated 2:48 PM EDT
VivoSim Labs, Inc., a pharmaceutical and biotechnology services company, provides testing of drugs and drug candidates in three-dimensional (3D) human tissue models of liver and intestine.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
VivoSim Labs, Inc. in the Healthcare sector is trading at $1.05 with a market capitalization of $3M. The stock is currently near its 52-week low of $0.94, remaining 48.0% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 32) — potential for technical mean-reversion
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|---|
| Total Revenue | $26,000↓ | $28,000↓ | $37,000↓ | $51,000↑ | $24,000 |
| Gross Profit | $26,000↓ | $28,000↓ | $37,000↓ | $51,000↑ | $22,000 |
| Operating Income | -$2.75M↓ | -$2.63M↑ | -$2.92M↑ | -$3.15M↑ | -$3.47M |
| Net Income | -$2.69M↓ | -$2.54M↑ | -$2.84M↓ | $6.85M↑ | -$3.45M |
Peer Comparison
JNJUNHPFE
Fundamentals
VivoSim Labs, Inc., a pharmaceutical and biotechnology services company, provides testing of drugs and drug candidates in three-dimensional (3D) human tissue models of liver and intestine. It offers partners liver and intestinal toxicology insights t...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$3.43M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-27.63%
Volume
Today's trading volume
679,479
Recent News
NIO January Deliveries Nearly Double Year On Year
EV maker opens 2026 with strong momentum
Top Midday Gainers
VivoSim Labs (VIVS) said late Thursday it signed agreements appointing JCBio as its distributor in S
BC-Most Active Stocks
GCL Global Holdings Ltd. 49,480,730 1.29
Wall Street Set to Open Lower Friday as Investors React to Trump's Choice of Warsh as Fed Chair
US stocks look set to open lower in Friday's trading session as investors seem calmed by President D
Rivian vs. NIO: Which EV Manufacturer Stock Is Worth Buying?
RIVN's upcoming R2 SUV, aggressive cost cuts and a multibillion-dollar Volkswagen partnership give it an edge over NIO in the EV stock debate.